CL2013000586A1 - Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta. - Google Patents

Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta.

Info

Publication number: CL2013000586A1
Authority: CL; Chile
Prior art keywords: tgf; patient; procedure; reducing; myocardial infarction
Prior art date: 2010-09-01

Application number

CL2013000586A

Other languages

English (en)

Inventor

Geoffrey Y Akita

Scott Lonning

Richard C Gregory Jr

Amelia B Kudej

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-01

Filing date

2013-02-28

Publication date

2013-08-30

2013-02-28 Application filed by Genzyme Corp filed Critical Genzyme Corp

2013-08-30 Publication of CL2013000586A1 publication Critical patent/CL2013000586A1/es

Links

230000002411 adverse Effects 0.000 title 1
239000002876 beta blocker Substances 0.000 title 1
208000010125 myocardial infarction Diseases 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Mycology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Physics & Mathematics (AREA)
Rheumatology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Diabetes (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)

CL2013000586A 2010-09-01 2013-02-28 Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta. CL2013000586A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37931510P	2010-09-01	2010-09-01

Publications (1)

Publication Number	Publication Date
CL2013000586A1 true CL2013000586A1 (es)	2013-08-30

Family

ID=44654454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000586A CL2013000586A1 (es)	2010-09-01	2013-02-28	Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta.

Country Status (19)

Country	Link
US (2)	US20130330352A1 (es)
EP (1)	EP2611831B1 (es)
JP (2)	JP6377348B2 (es)
KR (1)	KR101939965B1 (es)
CN (1)	CN103201292B (es)
BR (1)	BR112013004850B1 (es)
CA (1)	CA2809568C (es)
CL (1)	CL2013000586A1 (es)
ES (1)	ES2715177T3 (es)
IL (1)	IL225018A (es)
MX (1)	MX354535B (es)
MY (1)	MY165160A (es)
NZ (2)	NZ624382A (es)
PH (1)	PH12013500411A1 (es)
PL (1)	PL2611831T3 (es)
RU (1)	RU2637088C2 (es)
SG (2)	SG10201506909PA (es)
TR (1)	TR201903101T4 (es)
WO (1)	WO2012030394A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2553762T3 (es) *	2009-02-18	2015-12-11	Cormatrix Cardiovascular, Inc.	Composiciones y métodos para prevenir la arritmia cardiaca
KR102258457B1 (ko) *	2013-03-11	2021-05-31	젠자임 코포레이션	조작된 항-tgf-베타 항체 및 항원-결합 단편
CN105658672A (zh)	2013-08-22	2016-06-08	阿塞勒隆制药公司	TGF-β受体II型变体及其用途
CA2971186A1 (en)	2014-12-15	2016-06-23	The Regents Of The University Of California	Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US11253546B2 (en)	2014-12-15	2022-02-22	The Regents Of The University Of California	Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
CN116327952A (zh)	2015-08-04	2023-06-27	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
RS64053B1 (sr)	2015-10-30	2023-04-28	Univ California	Polipeptidi koji reaguju na transformišući faktor rasta – beta i postupci za njihovu upotrebu
TW201726744A (zh)	2016-01-11	2017-08-01	奧托德里克有限公司	用於檢測奧美沙坦(olmesartan)及改善治療高血壓之遵從性的組成物、裝置及方法
US20170218040A1 (en) *	2016-02-02	2017-08-03	Julio A. Camarero Palao	Proteolically resistant cyclotides with angiotensin 1-7 like activity
CA3033614A1 (en) *	2016-08-11	2018-02-15	Precithera, Inc.	Tgf-.beta. antagonist conjugates
DK3628049T3 (da)	2017-05-04	2023-08-14	Acceleron Pharma Inc	Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
CA3234324A1 (en)	2021-09-30	2023-04-06	Peptidream Inc.	Peptide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
EP0672142B1 (en)	1992-12-04	2001-02-28	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
PT1137941E (pt)	1998-12-10	2009-10-15	Brystol Myers Squibb Company	Esqueletos de proteínas para compostos miméticos de anticorpos e outras proteínas de ligação
US7763580B2 (en) *	1999-01-05	2010-07-27	University Of Utah Research Foundation	Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2561686C (en)	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
AP2764A (en) *	2005-01-31	2013-09-30	Mylan Lab Inc	Hydroxylated nebivolol metabolites
PT3520815T (pt) *	2005-02-08	2022-02-02	Genzyme Corp	Anticorpos contra tgfbeta
AP2011005824A0 (en) *	2009-01-26	2011-08-31	Intermune Inc	Methods for treating acute myocardial infarctions and associated disorders.
ITMI20110376A1 (it)	2011-03-10	2012-09-11	Wilic Sarl	Aerogeneratore raffreddato a fluido

2011
- 2011-09-01 US US13/819,393 patent/US20130330352A1/en not_active Abandoned
- 2011-09-01 MY MYPI2013000675A patent/MY165160A/en unknown
- 2011-09-01 CA CA2809568A patent/CA2809568C/en not_active Expired - Fee Related
- 2011-09-01 NZ NZ624382A patent/NZ624382A/en not_active IP Right Cessation
- 2011-09-01 CN CN201180052346.0A patent/CN103201292B/zh not_active Expired - Fee Related
- 2011-09-01 EP EP11758276.7A patent/EP2611831B1/en active Active
- 2011-09-01 NZ NZ608813A patent/NZ608813A/en not_active IP Right Cessation
- 2011-09-01 SG SG10201506909PA patent/SG10201506909PA/en unknown
- 2011-09-01 JP JP2013527063A patent/JP6377348B2/ja not_active Expired - Fee Related
- 2011-09-01 ES ES11758276T patent/ES2715177T3/es active Active
- 2011-09-01 BR BR112013004850A patent/BR112013004850B1/pt not_active IP Right Cessation
- 2011-09-01 SG SG2013013875A patent/SG187953A1/en unknown
- 2011-09-01 TR TR2019/03101T patent/TR201903101T4/tr unknown
- 2011-09-01 KR KR1020137008326A patent/KR101939965B1/ko not_active Expired - Fee Related
- 2011-09-01 WO PCT/US2011/001536 patent/WO2012030394A1/en not_active Ceased
- 2011-09-01 PL PL11758276T patent/PL2611831T3/pl unknown
- 2011-09-01 MX MX2013002390A patent/MX354535B/es active IP Right Grant
- 2011-09-01 RU RU2013114365A patent/RU2637088C2/ru active
- 2011-09-01 PH PH1/2013/500411A patent/PH12013500411A1/en unknown
2013
- 2013-02-28 IL IL225018A patent/IL225018A/en active IP Right Grant
- 2013-02-28 CL CL2013000586A patent/CL2013000586A1/es unknown
2016
- 2016-12-12 US US15/376,358 patent/US10633437B2/en not_active Expired - Fee Related
2017
- 2017-04-20 JP JP2017083499A patent/JP2017193543A/ja active Pending

Also Published As

Publication number	Publication date
TR201903101T4 (tr)	2019-03-21
JP2017193543A (ja)	2017-10-26
MX354535B (es)	2018-03-09
CN103201292B (zh)	2016-09-14
NZ608813A (en)	2014-11-28
CN103201292A (zh)	2013-07-10
US10633437B2 (en)	2020-04-28
CA2809568C (en)	2019-06-11
CA2809568A1 (en)	2012-03-08
ES2715177T3 (es)	2019-06-03
IL225018A (en)	2017-11-30
US20130330352A1 (en)	2013-12-12
SG187953A1 (en)	2013-03-28
MY165160A (en)	2018-02-28
NZ624382A (en)	2015-05-29
BR112013004850B1 (pt)	2020-04-07
AU2011296574B2 (en)	2015-12-03
WO2012030394A1 (en)	2012-03-08
PL2611831T3 (pl)	2019-05-31
SG10201506909PA (en)	2015-10-29
EP2611831B1 (en)	2018-12-12
MX2013002390A (es)	2013-08-27
BR112013004850A2 (pt)	2016-05-31
RU2637088C2 (ru)	2017-11-29
KR20130111550A (ko)	2013-10-10
EP2611831A1 (en)	2013-07-10
AU2011296574A1 (en)	2013-03-21
JP2013542179A (ja)	2013-11-21
PH12013500411A1 (en)	2022-03-30
JP6377348B2 (ja)	2018-08-22
RU2013114365A (ru)	2014-10-10
US20170233465A1 (en)	2017-08-17
KR101939965B1 (ko)	2019-01-18

Publication	Publication Date	Title
CL2013000586A1 (es)	2013-08-30	Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta.
NO20210424A1 (no)	2011-08-05	Fremgangsmåte for å utføre brønnoperasjoner
BRPI0910307A2 (pt)	2019-09-24	inibidores de hiv integrase
DK3419208T3 (da)	2021-04-26	Fremgangsmåde til diskontinuerlig modtagelsesdrift for long-term-evolution-advanced-bæreraggregering
CR20120576A (es)	2013-03-04	Inhibidores de pirazolil quinazolina cinasa
ME03376B (me)	2020-01-20	Makrociklička jedinjenja kао inhibiтori trk kinaze
EP2603600A4 (en)	2014-10-29	PEPTIDOMIMETIC MACROCYCLES
EP2346734A4 (en)	2013-01-02	ACTIVE WINGLET
FR2971145B1 (fr)	2014-04-25	Implant de corporectomie
EP3738544C0 (de)	2023-10-18	Dentalimplantat
IT1394860B1 (it)	2012-07-20	Composti farmaceutici
CO6781493A2 (es)	2013-10-31	Inhibidores de la faah
HRP20161771T1 (hr)	2017-02-24	Formulacije bendamustina
EP2411563A4 (en)	2013-06-26	IMPROVED CATHODE
FR2960763B1 (fr)	2013-08-02	Implant de suture
CR20140068A (es)	2014-08-18	Una formulación herbicida mejorada
EP2563127A4 (en)	2013-11-06	PROLYLCARBOXYPEPTIDASE INHIBITORS
SMT201600004B (it)	2016-02-25	Coniugato cristallino di naloxolo-peg
IL212019A0 (en)	2011-06-30	Hiv integrase inhibitors
IT1393930B1 (it)	2012-05-17	Composti farmaceutici
SMT201700122B (it)	2017-03-08	Dispositivo per la preparazione di una bevanda
IT1399637B1 (it)	2013-04-26	Procedimento per preparare una composizione di silice-allumina amorfa e relativa composizione di silice-allumina amorfa
EP2578161A4 (en)	2013-04-10	ULTRASOUND DEVICE
IT1398202B1 (it)	2013-02-14	Macchina per la preparazione di una bevanda
IT1395724B1 (it)	2012-10-19	Composti farmaceutici